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Objective: In an attempt for better treatment of bacterial infections and burn wounds,
plasterformulationscontainingdifferentconcentrationsofnorﬂoxacinwerepreparedus-
ing polymers like polyvinylpyrrolidone and polyvinyl alcohol and evaluated for physic-
ochemical parameters, in vitro drug release, antimicrobial activity, and burn wound
healing properties. The prepared formulations were compared with silver sulfadiazine
cream 1%, USP. Methods: Plaster formulations containing different concentrations of
norﬂoxacin were prepared by solvent casting method using combination of polymers
like polyvinylpyrrolidone and polyvinyl alcohol. These plasters were characterized for
drug content, thickness, percentage elongation, tensile strength, in vitro drug release
properties, and antimicrobial activity against various strains of aerobic and anaerobic
microorganisms. The wound healing property was evaluated by histopathological ex-
amination and by measuring the wound contraction. Results: The in vitro release and
in vitro skin permeation followed the ﬁrst-order kinetics followed by diffusion as dom-
inant release mechanism. In spite of the signiﬁcant antimicrobial and wound healing
effects produced by plasters, the observed values were less than the values obtained with
silver sulfadiazine 1% cream (P <. 05). Various histopathological changes observed
during the study period (days 1, 4, 8, and 12) also supported the wound healing process.
Conclusion: Based on the observed in vitro performances along with antimicrobial and
wound healing effects, the 5% norﬂoxacin transdermal plasters could be employed as an
alternative to commercial silver sulfadiazine 1% cream.
Ramakrishanan et al1 and Wang et al2 reported separately that anaerobic bacteria
are the causative organisms for infection in around 15% of burn-infected patients. Huo3
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reported that silver norﬂoxacin (NF) proved valuable in the treatment of burn wound
infection caused by invading organisms, particularly by silver sulfadiazine-resistant strain
of Pseudomonas.
Topical antibiotics can play an important role in prevention and treatment of many
primary cutaneous bacterial infections commonly seen in dermatological practice like lo-
calized superﬁcial infections due to surgery, injury, and abrasion.4 Topical antimicrobials
help in preventing entry of microorganism into wound, which leads to fast healing of
wounds. Quinolones belong to synthetic class of antimicrobial agents with potent antimi-
crobial activity which are effective orally and parentally for a wide variety of infectious
diseases.5 Norﬂoxacin, a broad-spectrum ﬂuoroquinolone antibacterial agent, is commonly
employed in the treatment of urinary and genital tract infections.6-8 It is a hydrophilic
ﬂuoroquinolone with unique physiochemical properties such as low water solubility and
partition coefﬁcient.9-11
The objective of the present study was to prepare transdermal plasters containing
different concentrations of NF and to evaluate burn wound-healing efﬁcacy in comparison
with marketed silver sulfadiazine 1% cream, USP.
METHODS
Norﬂoxacin (Pﬁscar India Ltd, Murthal, Haryana, India); polyvinylpyrrolidone (PVP), and
polyvinyl alcohol (PVA) (SD Fine Chemicals, Mumbai, Maharashtra, India). All other
chemicals used were of analytical grade, UV-spectrophotometer (Jasco V-530, Jasco Inc,
8649, Commerce Dr, Easton, MD 21601).
Table 1. Composition of the TDDS formulations containing norﬂoxacin
Ingredients
Formulation NF (g) PVP (g) PVA (g) Glycerin (g) DMSO (g) Water to (ml)
NF-1 1 2 1.6 ... . .. 100
NF-2 2 2 1.6 ... . .. 100
NF-3 3 2 1.6 ... . .. 100
NF-4 4 2 1.6 ... . .. 100
NF-5 5 2 1.6 ... . .. 100
NF-6 5 2 1.6 0.10 . .. 100
NF-7 5 2 1.6 0.20 . .. 100
NF-8 5 2 1.6 0.30 . .. 100
NF-9 5 2 1.6 0.10 1.0 100
NF-10 5 2 1.6 0.10 2.0 100
NF-11 5 2 1.6 0.10 3.0 100
NF-12 5 2 1.6 0.10 2.0 100
Preparation of transdermal plasters
TransdermalplasterscontainingNFwerepreparedbycastingmethodonmercurysurface12
usingPVP,PVAaspolymersaccordingtothecompositiongiveninTable1.Polymersolution
was prepared by heating a mixture of PVP and PVA (1:0.8) in water (about 40 mL) for
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30 minutes, until a clear solution was obtained. The above ratio was selected on the basis
of a pilot study. Weighed quantity of NF was dissolved in the above polymer solution and
volume was made up to 100 mL with water. Four milliliters of the solution was poured onto
mercury surface contained in a square glass mould of 4 cm × 4 cm (fabricated locally).
The glass moulds were placed on a leveled surface and the solution was allowed to cool
and solidify at ambient conditions for 24 hours. The moulds were kept in vacuum oven at
40◦C, 400 mm of mercury for 48 hours.13 The dried plaster ﬁlms were removed from the
moulds and 0.5-cm edges were cut along all 4 sides. Five formulations containing varying
concentrations of NF (NF-1 to NF-5) as given in Table 1 were prepared.
The plaster ﬁlms NF-1 to NF-5 were subjected to in vitro release studies to select the
plaster exhibiting the maximum release. In the selected formulation with maximum in vitro
release, glycerin was incorporated (as plasticizer) in concentrations given in Table 1 and
NF-6 to NF-8 were prepared in a similar way as described earlier. Based on the physical
parameters such as ﬂexibility, texture, and ease of fabrication, NF-6 with 0.1 g/100 mL of
glycerinwasconsideredasoptimumconcentration.Inthisoptimizedformulation,dimethyl
sulphoxide (DMSO) was incorporated as penetration enhancer at 3 different concentrations
(Table 1) to prepare NF-9 to NF-11. The effect of different concentrations of DMSO on the
physical properties and release rate of the drug from the plasters was studied to select the
best formulation. The ﬁnal formulation NF-12 was prepared with the selected optimized
concentration of the drug and the above ingredients.
Characterization of transdermal plasters
Plasters were visually observed for color, clarity, texture, and ﬂexibility.
 Thickness14 of plaster ﬁlms was measured using a digital vernier screw gauge (Ultra
Science Aids, Bangalore, India) at different places of the plasters and average thickness
was calculated.
 Weight15 of 6 individual plaster ﬁlms of 3 cm × 3 cm was determined using an electronic
balance with sensitivity of 0.1 mg (Ohause Corporation, Tokyo, Japan) and the average
weight was calculated. The test was performed on ﬁlms that were equilibrated under
anhydrous calcium chloride in a desiccator for 24 hours.
 Folding endurance15 was determined by folding and opening the plaster ﬁlm at the same
place repeatedly for 250 times or until a break developed at the place of folding. The
result was expressed as the number of times the plasters was folded to develop a break
(if a break developed).
Uniformity of weight
Sixpatchesfromdifferentﬁlms(1×1cm 2)wereweighedindividuallyusingdigitalbalance
(Ohause Corporation, Tokyo, Japan), and the average weight was calculated.
Percentage elongation at brake and tensile strength16
Percentage elongation at brake was determined by using the tensile strength apparatus
(fabricated locally). The plasters were cut into a size of 3 cm × 1-cm rectangular strips.
One end of the strip along its length was clamped to the tensile strength testing apparatus
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and the other end was attached to a movable rod. The movable rod was attached to a pan
with the help of a nonstretchable string through a pulley. Weights were carefully added
onto the pan and increased gradually. The elongation of the plaster was determined by
measuring the distance moved by the pointer on a graph paper after addition of the weight
each time. The weights were added, until the plaster was broken. Percentage elongation was
determined using the following formula:
Percentage elongation at break point =
(Lw − L) × 100
L
where L = initial length (in centimeter) of the plaster, and Lw = length (in centimeter) of
the plaster when weight is added.
The tensile strength of the plaster was determined using the following formula:
Tensile strength =
W
a × b
×
l +  l
l
where a = width (cm), b = thickness (cm), l = length (cm) of the test plaster strip,  l =
elongation (cm) at the break point , and W = weight (g) required to break the plaster.
Percent moisture absorption
Weighed (w1) separately 6 plasters each of 1 cm2 and equilibrated over anhydrous calcium
chloride for 1 week. Three plasters were exposed to ambient conditions of humidity (75%-
85% RH, 28◦C-32◦C) and the other 3 to saturation humidity conditions (100% RH, 28◦C-
32◦C) at room temperature for 2 days. Weight of each plaster (w2) was determined to
calculate the weight gained by each plasters. Percent moisture absorption17 was calculated
by using the following equation:
Percent moisture absorption =
(w2 − w1) × 100
w1
Drug content and content uniformity
Transdermal plasters of each formulation were cut into pieces of 1 cm × 1 cm to determine
the drug content and content uniformity.18 Six plasters, separately, were transferred into a
glass mortar and triturated with 10 mL of 1% v/v acetic acid for 30 minutes. The contents
were transferred into a 100-mL volumetric ﬂask containing small amount of methanol and
shakencontinuouslyfor1hourtoextractthedrugfrompolymer.Theresultingsolutionwas
ﬁltered through Whatman-1 ﬁlter paper and the drug content in the ﬁltrate was determined
by measuring the absorbance at 277.6 nm. Drug content per 1 cm2 of plaster was calculated
by regression equation.
Drug-polymer interaction studies
Thedrug-polymerinteractionswerestudiedbyTLC(thinlayerchromatography)analysis,19
Fourier transformed infrared (FT-IR) spectroscopy using Shimadzu FTIR-8400S Fourier
transform infrared spectrophotometer,12 and differential scanning calorimetry (DSC) anal-
ysis using Shimadzu DSC-50 Thermal Analyzer.20
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In vitro diffusion studies
In vitro diffusion studies for all plaster formulations were carried out using Keshary-Chein
typediffusioncellthatcompriseddonorandreceptorcells.12,20,21 Twentypercentv/vacetic
acid was used as receptor media. The dialysis membrane (25 cm2) was soaked in water for
a while and then for 2 hours in isotonic phosphate buffer solution, pH 7.4 (100 mL), prior
to be mounted on the diffusion cell.
The membrane was tied securely to one end of the diffusion cell tube, the other end
kept open to the ambient conditions. For this purpose, transdermal plaster of 1 cm2 was
placed into the donor compartment of the diffusion cell that was immersed in the receptor
compartment containing20 mL of medium, which was continuouslystirred using magnetic
Teﬂon-coated bead. The entire system was maintained at 37 ± 1◦C for 6 hours. An aliquot
of 2 mL was withdrawn at 0, 1, 2, 3, 4, 5, 6, 7, 8, 12, 16, 20, and 24 hours. After each
withdrawal, the diffusion medium was replaced with an equal volume of fresh diffusion
medium maintained at 37 ± 1◦C.
From the withdrawn aliquot of 2 mL, 1 mL was transferred in 100-mL volumetric
ﬂask, suitably diluted and the NF content was estimated spectrophotometrically at 277.6
nm. Average of 3 determinations was used to calculate the cumulative percent drug release
at each time interval.
In vitro skin permeability studies
This study was carried out for the best 3 formulations that exhibited the higher drug
release through dialysis membrane. In vitro skin permeability studies were undertaken
using Keshary-Chein diffusion cell12 in a similar way as described earlier but by using
rat abdominal skin, instead of dialysis membrane. The rat skin was obtained from the
abdominal portion of an albino rat after sacriﬁcing the animal. The hair and fat were
removed after treating the skin with 0.32 mol L-1 ammonia solution for 30 minutes.18
The skin was tied to the KC diffusion cell (donor cell) such that the stratum corneum side
of the skin was kept in intimate contact with the release surface of the formulation in the
donor cell. All experiments were carried out in triplicate.
Kinetic analysis of release and skin permeability data
The release and skin permeability data from the best 3 transdermal plaster formulations
were subjected to the kinetic analysis to establish the drug-release mechanism. The release
and permeation data were ﬁtted to zero-order,22 ﬁrst-order,23 matrix (Higuchi matrix),24
and Hixson-Crowell equations.25
Comparison of in vitro release and in vitro permeation proﬁles
The in vitro release and in vitro skin permeation proﬁles of the best among the 3 formula-
tions in each case were compared for similarity. The in vitro release and in vitro permeation
proﬁles of each of the 3 selected transdermal plaster formulations were compared for simi-
laritywiththatofthecommercialsilversulfadiazine1%cream,USP.Amodel-independent
approach was used employing a difference factor ( f1) and a similarity factor ( f2)a sg i v e n
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in below equations, respectively26,27:
f1 =
 
[Rt − Tt]
 
Rt
× 100
f2 = 50.Log
⎡
⎣ 1
 
1 + 1
n
 
(Rt − Tt)2
× 100
⎤
⎦
Where Rt and Tt are % dissolved for reference and test formulation at each time point and
n is the number of time points dissolution proﬁle. The time intervals used to study the f1
and f2 were up to 420 minutes.
The f1 valueincreasesproportionallybecauseofthedissimilaritybetweenthe2release
proﬁles. If f1 value lies between 0 and 15 and f2value of 2 drug release proﬁles is between
50 and 100, then these 2 drug proﬁles are considered similar. Value less than 50 indicates
difference between the release proﬁles. The value of f2 = 50 reﬂects 10% difference; when
value is >greater than 50, the difference between R and T is less than 10%.28
Correlation of in vitro release and in vitro skin permeation data
Theinvitropercentdrugreleasefromselectedtransdermalplasterformulationsatdifferent
time intervals was plotted against the in vitro percent drug permeation at different time
intervals. The R2 value was calculated after regression analysis. A linear relationship
between the above 2 parameters would be indicated by the R2 values approaching to 1.29
Stability studies
Stability studies on selected formulations were conducted according to International Con-
ference on Harmonization guidelines. Drug-loaded transdermal plaster formulations were
wrapped separately in aluminum foil and placed in polyethylene bag. The samples were
stored at ambient conditions, 40 ± 2◦C and 75 ± 5% RH for 6 months. Three samples of
each formulation were withdrawn at 0, 30, 60, 90, and 180 days and analyzed visually for
any changes in their physical characteristics and drug content as described earlier and the
shelf life was determined.30
Skin irritation test
Skin irritation was tested to ﬁnd any allergic reactions caused by the application of topi-
cal/transdermal formulations. Six rabbits of either sex weighing 1.3 to 1.5 kg were used in
thisstudy.Theabdominalhairswereremovedbyshaving.Theshavedskinwascleanedwith
70% alcohol and allowed to dry. Selected plaster formulation containing NF was applied
on to the shaved skin of each rabbit and left in contact for 23 hours daily for 22 days.
The skin was observed regularly for the study period for erythema (reddening of the skin),
inﬂammation, contact dermatitis, or any change.31
Microbiological studies
The antibacterial activity of various plaster formulations containing NF against various
strains of aerobic and anaerobic microorganisms was evaluated by cup-plate method.
Bacillus subtilis, Staphylococcus aureus, Escherichia coli, Pseudomonas aeruginosa (aer-
obic organisms), and Bacteriodes fragilis (anaerobic organism) were used for testing the
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antibacterial activity. Nutrient agar medium was used for aerobic bacterial cultures, and
blood agar medium was used for B fragilis.
Plaster ﬁlms containing NF were cut into circular pieces of 6-mm diameter and placed
on the agar medium in plates. Silver sulphadiazine 1% cream (100 mg) was dispersed
in 1 mL of water. Filter paper disks of 6-mm diameter were impregnated with the above
dispersionandwereplacedontheagarmediumplates.Onesamplewasplacedoneachplate.
Theplateswerepreparedintriplicate.Plateswithaerobicorganismswereincubatedat37±
0.2◦C for 24 hours under aerobic conditions, while B fragilis cultures were incubated under
carbondioxideatmosphereinananaerobicjarat37±0.2◦Cfor48hours.14 Inhibitionzone
diameters were measured with the help of zone reader (Digital Antibiotech Zone Reader,
Effem Technologies New Delhi, India).32,33,34
Burn wound healing studies
The experiments were carried out as per the guidelines of Animal Ethics Committee.
Healthy Wistar albino rats weighing between 150 and 180 g were used for burn wound
healing. The animals were divided into various groups, each group containing 6 animals.
The untreated group was taken as control. The dorsum of each rat was shaved and the
burn wounds were inﬂicted on overnight-starved animals under pentobarbitone sodium
(6 mg/100 g, ip), anesthesia. A 2 cm × 2-cm metal cylinder was placed on the shaven back
of the animals. Melted wax at 80◦C was poured into the metal cylinder and the wax was
allowed to solidify. Eight minutes after this or until the wax was completely solidiﬁed, the
metalcylindercontainingwaxadheringtotheskinwasgentlyremovedtoinﬂictadistinctly
demarkedburnwound.35,36 Inallcases,theburnswerethirddegree,andthepercentagewas
in 1 sample unit area according to the rule of nines, that is 9% of the body surface involved.
Selected NF transdermal plaster ﬁlms and the marketed Silver sulfadiazine 1% cream
USP (500 mg) were applied to the wound-inﬂicted areas of animals every day from the
day 1 until day 12. The epithelialization period and wound contraction was observed in the
study. The epithelializationperiod was monitored by recording the number of days required
for eschar to fall off from the burn wound surface without leaving a raw wound behind.
Theanimalswereobservedforwoundhealingbymeasuringthewoundcontraction(tracing
the raw wound area on a transparent polythene paper that was retraced on graph paper (to
assess the area) up to 12th day postwounding. The wound contraction was calculated as
percentage of original wound size for each animal of a group.37
Histopathological studies
Theratswereanesthetizedandtheburnedskintissuesampleswerecollectedfromrats(days
1, 4, 8, and 12) for histopathological examinations. The samples were ﬁxed in 10% neutral
buffered formalin and were cut into 5-μm sections and stained with hematoxylin and eosin
(H&E) and examined by light microscopy for morphological changes. A histopathologist,
blinded to the study, was assigned to analyze and grade the histological changes of each
group.37,38
Statistical analysis
Data pertaining to antimicrobial and burn wound healing activity were expressed as
mean ± SD and the data were analyzed by one-way analysis of variance (ANOVA) with the
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Tukey test for multiple comparisons using Jandel Sigma Stat statistical software, version
2.0. In all the analysis P< .05 was considered as statistically signiﬁcant.
RESULTS
The average thickness of the plasters ranged between 143 and 160 μm. The tensile strength
variedfrom22to44g/cm2.Amongthevariousingredientspresentintheformulations,PVP
and glycerin were responsible for absorbing moisture. Drug loading varied from 91.1% to
97.6%.
Drug-polymer interaction studies
A minute variations of R f values of NF as pure drug (R f = 0.27) as compared with that
in transdermal plasters given in Table 2 indicated the compatibility of drug with PVP and
PVA. This variation was expected to be of the normal experimental nature.
The drug was found identiﬁable by the presence of the characteristics bands. All the
characteristic bands of NF were observed in the drug-polymer mixture. The ﬁndings are
suggestive of the absence of any incompatibility between NF and polymers (Fig 1).
Table 2. TLC data of transdermal plasters containing norﬂoxacin
Formulation NF-1 NF-2 NF-3 NF-4 NF-5 NF-6
R f
∗ 0.26 (0.02) 0.27 (0.05) 0.25 (0.03) 0.27 (0.08) 0.26 (0.04) 0.27 (0.06)
Formulation NF-7 NF-8 NF-9 NF-10 NF-11 NF-12
R f
∗ 0.24 (0.02) 0.27 (0.04) 0.23 (0.05) 0.28 (0.06) 0.27 (0.02) 0.25 (0.04)
∗Mean and standard deviation (in parenthesis) of 6 readings.
Figure 1. FTIRspectraof(A)Norﬂoxacinand(B)6-month-oldnorﬂoxacintopicalﬁlm(NF-11).
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Figure 2. DSC Thermogram of (A) NF; (B) PVA; (C) PVP; (D) NF-PVP-PVA (PM); (E) 6-
month-old NF topical ﬁlm (NF-11). NF indicates norﬂoxacin; PM, physical mixture; PVA,
polyvinyl alcohol; PVP, polyvinyl pyrrolidone.
The obtained DSC thermograms demonstrated a sharp melting endotherm at 227◦C
corresponding to the melting temperature of pure NF (Fig 2). It further indicated that the
drug dispersed uniformly into the molten mass of polymers. The endotherm representing
PVA was clearly distinguishable from the drug and PVP. The DSC further supported that
NF was compatible with the polymers under study.
In vitro release studies
The comparative release of NF from various formulations was shown in Figures 3 and 4.
Figure 3. In vitro release proﬁle of norﬂoxacin transdermal formulations (NF-1–NF-6).
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Figure 4. In vitro release proﬁle of norﬂoxacin transdermal formulations (NF-7–NF-12).
Figure 5. In vitro skin permeation proﬁle of selected norﬂoxacin transdermal formulations
(NF-10, NF-11, and NF-12).
In vitro skin permeability
The comparative release of NF from various selected formulations was shown in Figure 5.
In vitro release and in vitro skin permeation—kinetics
The release of all plasters followed the ﬁrst-order release kinetics, since the correlation
coefﬁcient (R2) for ﬁrst order was higher in comparison to zero-order release. The results
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are in agreement with the previous investigations by Wahid et al (2008).39 When the values
of the coefﬁcients for “t (time)” were compared, the in vitro release of NF from NF-11 (x
coefﬁcient was 0.017) and in vitro skin permeation for NF-11 (x coefﬁcient 0.0061) was
found to be marginally higher in comparison to the other selected transdermal plasters.
In vitro release–in vitro skin permeation correlation
As indicated by the R2 values higher than 0.97, a good correlation between the in vitro
releaseandinvitropermeationwasdemonstratedforall3formulations.Thelowervaluesof
coefﬁcientsofx coordinatefurthersupportagoodcorrelation.However,thebestcorrelation
(R2 = 0.9844) was found for the NF-10.
Comparison of in vitro release and in vitro permeation proﬁles
The values of dissimilarity factor ( f1) and similarity factor ( f2) for the in vitro release and
in vitro permeation are given in Table 3 and Figures 6 and 7.
Table 3. Analysis of f1 (difference factor) and f2
(similarity factor) value of NF-11 with marketed
silver sulfadiazine 1% cream, USP
NF-11
Formulation⇒ f 1 f 2
In vitro release 62.91 24.56
In vitro skin permeation 41.23 65.73
Figure 6. Analysisofinvitroreleaseproﬁlefor f1 (differencefactor)and f2 (similarityfactor)
of NF-11 with marketed Silver sulfadiazine 1% cream, USP.
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Figure 7. Analysis of in vitro skin permeation proﬁle for f1 (difference factor) and f2 (simi-
larity factor) of NF-11 with marketed Silver sulfadiazine 1% cream, USP.
Stability studies
Allplastersremainedtransparentandnovisualdifferencesincolorortexturewereobserved.
The degradation of NF in transdermal plasters followed ﬁrst order, as the values of R2
for time versus log percent degradation graph were high. Degradation of all the three
formulations followed almost to the same rate and extent. However, real-time studies
for a period of 2 years are required to establish the stability of developed transdermal
plasters.
Skin irritation test
The skin irritation study indicated that neither the drug nor its components caused any
edema or inﬂammation in or around the patch area during the period of study; however,
reddeningoftheskinwasobservedafter7thday,attheapplicationsiteoftransdermalplaster.
However, the reddening of the skin disappeared after the discontinuation. Reddening of the
skin may be due to the presence of DMSO in the formulation.
Antimicrobial activity
As indicated by ANOVA statistics followed by the Tukey test, NF plaster (NF-11) had
exhibited signiﬁcant antibacterial activity against various strains of aerobic and anaerobic
microorganisms that was in good agreement with silver sulfadiazine 1% cream, USP and
the results obtained are shown in Table 4 and Figure 8.
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Table 4. Antimicrobial activity of transdermal plasters (n = 6)
Inhibition Zone Diameter, mean (SD), mm
Formulation B subtilis S aureus E coli P aeruginosa B fragilis
NF-10 31.07*,† (0.97) 43.18*,† (0.93) 38.94* (0.92) 34.48* (0.93) 40.29*,† (0.88)
NF-11 34.13*,†,‡ (0.77) 41.29*,†,‡ (0.88) 38.80* (0.94) 37.15*,†,‡ (0.91) 42.51*,†,‡ (0.88)
NF-12 37.26* (0.86) 30.50* (0.72) 39.21* (0.78) 35.22* (0.79) 37.18* (0.75)
Silver sulfadiazine 45.33 (0.78) 51.22 (0.86) 48.31 (0.72) 44.72 (0.98) 45.33 (0.78)
1% cream USP
∗P <. 05 Vs silver sulfadiazine 1% cream, USP.
†P <. 05 Vs NF-12.
‡P <. 05 Vs NF-10.
Figure 8. Comparativeanalysisofanti-bacterialactivityofselectedformulationsofnorﬂoxacin
transdermal plasters with silver sulfadiazine 1% cream, USP. ∗P <. 05 vs silver sulfadiazine
1% cream, USP. aP <. 05 vs NF-10; bP <. 05 vs NF-12.
Burn wound healing activity
No mortality was observed in the animals during the study period. The mean period of
epithelialization was found to decrease signiﬁcantly in comparison to control (52.2 ± 1.2).
However, no signiﬁcant difference was observed in the mean values of NF-11 (27.0 ± 1.7)
and silver sulfadiazine 1% cream, USP (25.9 ± 1.3).
The difference between the mean percent burn wound contraction of the NF plaster
treated animals as compared to control was found to be statistically signiﬁcant. All the
prepared formulations, including silver sulfadiazine 1% cream, USP, had shown wound
healing activity (P< .05) in healthy male Wistar albino rats. Burn wound healing studies
revealedamaximumpercentwoundhealingof57.15±0.86%withNF-11incomparisonto
silver sulfadiazine formulation available on the market, showing 84.34 ± 0.49% of wound
healing within 12 days (Table 5 and Fig 9).
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Table 5. Percent burn wound contraction of transdermal norﬂoxacin plaster∗
% Wound Contraction Period of
Formulations ↓ Epithelialization
Days → 4th day 8th day 12th day (days)
Control 16.13† (0.78) 21.21† (0.99) 30.42† (0.95) 52.2† (1.2)
NF-10 33.12†,‡ (1.06) 41.34†,‡ (0.96) 47.13†,‡ (0.89) 34.90†,‡ (1.5)
NF-11 47.10†,‡,§,  (0.93) 50.13†,‡,§,  (1.01) 57.15 †,‡,§,  (0.86) 27.00‡,§,  (1.7)
NF-12 39.12 †,‡,§ (0.99) 46.13†,‡,§ (0.75) 51.12†,‡,§ (0.90) 30.5†,‡,§ (1.6)
Silver sulfadiazine 52.00 (1.45) 71.87 (0.98) 84.34 (0.49) 25.9 (1.3)
1% Cream, USP
∗ Values in parenthesis indicate the standard deviation (n = 6).
†P <. 05 vs Silver sulfadiazine 1% cream, USP.
‡P <. 05 vs control.
§P <. 05 vs NF-10.
 P <. 05 vs NF-12.
Figure 9. Comparative analysis of percent wound contraction of selected transdermal plasters of
norﬂoxacin with silver sulfadiazine 1% cream, USP. ∗P <. 05 vs Silver sulfadiazine 1% cream,
USP. aP <. 05 vs control; bP <. 05 vs NF-10; cP <. 05 vs NF-12.
Histopathological studies
The various histopathological changes observed during the study period (days 1, 4, 8, and
12) are tabulated in Table 6 and illustrated in Figures 10, 11, and 12.
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Table 6. Comparative evaluation of histopathological observations of selected norﬂoxacin topical
ﬁlm with silver sulfadiazine 1% cream, USP
Day NF-11 SS
Day 1 Ulceration and burns on the skin and
subcutaneous tissue, coagulative necrosis
Presence of ulcer on surface due to injury,
ﬁlled with slough and necrotic debris
Day 4 Extensive granulation tissue,
reepithelialization, moderate scab formation,
good proliferation, numerous inﬂammatory
macrophages, and ﬁbroblasts seen
Scab formed, beneath which a clot composed
of ﬁbrin, red blood cells, and platelets are
formed. Inﬂammatory cells like
macrophages and neutrophils migrate to the
site
Day 8 Fibroblasts proliferation, collagen laying down,
angiogenesis, neovascularization, wound
contraction seen
Areas of ﬁbroblast proliferation, new blood
vessel formation, wound begin to contract
Day 12 Prominent wound contraction, collagen, and
ﬁbrosis are increased because of healing
process resulting in prominent scar
formation, cellularity reduced
Collagen is laid down signiﬁcantly,
inﬂammatory cells are reduced because of
the healing process, and presence of ﬁbrous
scar is noticed
Figure 10. Microscopic appearance of burned skin on the 4th day.
DISCUSSION
All the plasters were nonsticky. However, with increase in PVP, the characteristics of the
plaster were found to change from nonsticky through semisticky to sticky. Based on this
property, transdermal plaster containing 1.0 g/100 mL of PVP and 0.8 g/100 mL of PVA
was ﬁnalized, which was observed to be nonsticky, tough, and easily moldable. Addition of
glycerin in plasters NF-6 to NF-8 increased the thickness marginally, but the tackiness was
comparatively enhanced. On the basis of these observations, 0.1 g of glycerin/100 mL was
ﬁxed as optimum (NF-6). The gradual increase in concentration of DMSO in the plasters
NF-9 to NF-11 resulted in marginal increase in the thickness of the plasters. The weights
were uniform on the basis of the considerations of dry weight of the ingredients.
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Figure 11. Microscopic appearance of burned skin on the 8th day.
Figure 12. Microscopic appearance of burned skin on the 12th day.
On the basis of earlier studies, PVA:PVP in 1:0.8 was selected as a optimized ratio for
the preparation of transdermal plasters. However, addition of glycerin and DMSO did not
inﬂuence the tensile strength. Among the various ingredients present in the formulations,
PVP and glycerin were responsible for absorbing moisture.
FTIR, DSC, and IR spectral studies performed on the ﬁlms indicated no interaction
between the drug and polymers. The drug was found identiﬁable by the presence of the
characteristicsbands.All thecharacteristicbandsofNF were observedin thedrug-polymer
mixture.
Higher concentration of glycerin (above 0.1 g/100 mL) produced slight increase in
release of NF but the ﬁlms were found to be tacky and difﬁcult to peel off from the surface.
Glycerinwasresponsiblefortheincreaseintheﬂexibilityoftheﬁlm.Astheconcentrationof
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DMSOwasincreased(NF-9toNF-11),thereleaseofNFincreasedfrom43.12%to62.66%
at24hours(Fig.4).The62.66%releaseofdrugfromNF-11wassomewhatcomparablewith
the 54.27% from NF-10, when DMSO concentration was increased from 2.0 g/100 mL to
3.0g/100mL.AlthoughthemaximumreleasewasfoundwithformulationNF-11(62.66%),
which contained 3% DMSO, but NF-10 (54.27% release) was regarded as the best formu-
lation based on the physicochemical properties. The formulation NF-10 contained 2.0 g/
100 mL of DMSO. PVP acts as nucleating agent that retards the crystallization of NF and
hence enhances the release of the drug from matrix by sustaining it in an amorphous form.
With the increase in the concentration of DMSO, the in vitro skin permeability of
NF was shown to be increased (Table 1). Maximum in vitro skin permeation of 29.12% of
NF was observed from NF-11 (Fig 5), which contained a higher concentration of DMSO
(3.0 g/100 mL). This higher in vitro skin permeability is reﬂective of DMSO as an effective
permeability enhancer. The extent of in vitro release of drug through dialysis membrane
was observed to be 20% to 30% higher when compared to in vitro skin permeability. Lower
values of standard deviation are suggestive of the reliability and reproducibility of the
experimentalmethods.TheﬁndingssupportedtheskinpenetrationenhancementbyDMSO.
TheﬁndingsofthisstudyaresuggestiveofthesuperiorityofNF-10,NF-11,andNF-12
in terms of physical properties, in vitro release proﬁle as well as skin permeation proﬁles.
Furtherstatisticalanalysiswasdoneontheabove3(NF-10,NF-11,andNF-12)formulations
to determine the rate kineticsand mechanismof release.The releaseof all plastersfollowed
the ﬁrst-order release kinetics and the release mechanism, as indicated by the higher
R2 values, was diffusion rate controlled following Higuchi model. As indicated by the
coefﬁcientsof“squareroott(time)”valuestheinvitroreleaseofNFfromNF-11washigher
(x coefﬁcient was 13.75) whereas in vitro skin permeation was higher for NF-10 (4.857).
The value of f1 greater than 15 and f2 lower than 50 revealed that transdermal plaster
(NF-11) was inequivalent to the commercial silver sulfadiazine 1% cream, USP. This
implied that the polymer matrix retarded the drug release from the fabricated transdermal
plaster. In terms of in vitro skin permeation, the f1 higher than 15 indicated dissimilarity of
the permeation of drug from test transdermal plaster and reference formulation (marketed
silver sulfadiazine 1% cream, USP) implying a corresponding slow permeation from test
formulation. Although a similarity factor ( f2) greater than 50 indicates the similarity of 2
formulations, yet the permeation proﬁle (Fig. 7) along with higher f1 is sufﬁcient to infer
that the test formulation permeation is not similar.
CONCLUSION
Norﬂoxacinplasterswereeasytoprepareandpreventmicroorganismsrecessonthewound.
The physical characteristics, such as thickness, average weight, consistency, elongation,
tensile strength, moisture absorption, and drug content of NF plasters, were suitable. The
polymer-drug interaction study did not show any incompatibility. The in vitro release of
drug from the plaster followed the ﬁrst-order kinetics followed by diffusion as a prominent
release mechanism. The in vitro release was increased with increase in glycerin (ﬂexibility
enhancer) and dimethyl sulfoxide (penetration enhancer). In spite of the signiﬁcant antimi-
crobial and wound healing effects produced by plasters, the observed values were less than
the values obtained with silver sulfadiazine 1% cream (P < .05). The polymers in plaster
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retarded the release of the drug leading to a dissimilar release proﬁle to that of the silver
sulfadiazine 1% cream, USP.
Based on the observed in vitro performances along with antimicrobial and wound
healing effects, the 5% NF transdermal plasters could be employed as an alternative to
commercial silver sulfadiazine 1% cream. The therapeutic potential of these plasters may
motivate researchers for its further exploitation for their commercial viability. This innova-
tive mode of formulation can be employed for making burn wound healing process more
effective.
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